Induced Genetic Deletion of Cell Division Autoantigen 1 in Adulthood Attenuates Diabetes-Associated Renal Fibrosis

Pacific Huynh1, Yuxin Yang1, Hua Tian1

  • 1Department of Diabetes, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.

Insights

Targeting Cell Division Autoantigen 1 (CDA1) after diabetes onset in mice can reduce kidney fibrosis. Inhibiting CDA1 attenuated key markers of renal injury and extracellular matrix accumulation in diabetic kidney disease models.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pathology

Background:

  • Cell Division Autoantigen 1 (CDA1) enhances transforming growth factor beta (TGFβ) signaling, contributing to fibrosis in diabetic kidney disease (DKD).
  • Previous studies used global CDA1 gene deletion models to show its role in DKD.
  • The effect of CDA1 inhibition after diabetes onset in the presence of CDA1 remains unclear.

Purpose of the Study:

  • To investigate if inhibiting CDA1 activity after diabetes onset can attenuate renal fibrosis in vivo.
  • To examine the therapeutic potential of targeting CDA1 in established diabetic kidney disease.

Main Methods:

  • Utilized a tamoxifen-inducible Cre-Lox system (ERCre-LoxP) for adult-onset genetic deletion of CDA1 in mice.
  • Induced diabetes using streptozotocin (STZ) in male mice (6-8 weeks old).
  • Administered tamoxifen to induce CDA1 deletion in diabetic and control mice, analyzing kidney tissues 5 weeks post-deletion.

Main Results:

  • Tamoxifen administration reduced CDA1 gene expression by approximately 80% in CDA1Flox/ERCre mice.
  • Diabetic mice showed increased renal levels of phosphorylated Smad3 and profibrotic genes.
  • Induced CDA1 deletion attenuated the accumulation of extracellular matrix proteins (collagens III and IV) in diabetic kidneys.

Conclusions:

  • Targeting CDA1 after the onset of diabetes in mice with pre-existing CDA1 expression can attenuate diabetes-associated renal injury.
  • Inhibition of CDA1 shows promise as a therapeutic strategy to reduce kidney fibrosis in diabetic kidney disease.
  • These findings provide a rationale for targeting the CDA1 pathway in DKD treatment.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...